Design and organic synthesis of non-carbohydrate glycomimetics towards galectin-3 inhibitors as drug leads
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with neuroinflammation and microglial dysregulation. Galectin-3 (gal-3), a β-galactoside-binding protein expressed in microglia, has been identified as an upstream regulator of neuroinflammatory responses and is increasingly recognized as a potential therapeutic target in AD. This Master’s thesis focuses on the design
